Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABOCHILD phase II cabozantinib in hepatocellular carcinoma with Child-Pugh B7-8 liver function
2019-001075-36Phase 2Terminated
- Sponsor
- University Medical Center Mainz
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by University Medical Center Mainz. Started Feb 2020; status: terminated.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2019-001075-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001075-36.